Please login to the form below

Not currently logged in

MSD forms pneumococcal partnership

MSD and Serum Institute of India have formed a partnership to develop a pneumococcal conjugate vaccine

MSD, known as Merck in the US and Canada, and Serum Institute of India are to work together to develop and commercialise a pneumococcal conjugate vaccine (PCV) for use in emerging and developing countries. 

The companies will form a product advisory committee to oversee the activities required to develop and seek approval for PCV and pursue World Health Organisation (WHO) prequalification. 

Under the terms of the agreement, Merck, through an affiliate, will receive specific rights to market PCV in certain designated territories and Serum will receive specific rights in other territories. Both companies will contribute to the development and manufacture of PCV. This collaboration does not impact the ongoing vaccine development programmes in both the organisations.

Julie L Gerberding, president of Merck Vaccines, said: "Working side by side with Serum gives us the best chance of developing and bringing a product to the market that will help to protect more babies and children.

"Expanding vaccine access to emerging and developing markets is a top priority and we feel strongly that this collaboration will be a giant step toward impacting the devastation of pneumococcal disease."

Financial details of the agreement have not been disclosed.

9th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...